Background: In settings where CD4-testing is not available, alternative markers to start paediatric anti-retroviral therapy (ART) could be used. A comprehensive evaluation of these markers has not been performed.
Background
HIV (human immunodeficiency virus) is a major cause of childhood morbidity and mortality in sub-Saharan Africa, where 90% of all HIV-infected children live (1, 2) .
Malawi is one of the most heavily affected countries with an estimated one million infected persons, including more than 120.000 children (2, 3) . In the absence of antiretroviral therapy (ART), the median survival of vertically infected African children is only 2 years (4) . Increased access to ART has radically improved survival of these HIV-infected children (4, 5) . Until 2013, the World Health Organization (WHO) recommended to commence ART in children two years of age or older based on an algorithm, using CD4 percentages or counts (6, 7) . Since 2013 the WHO has recently modified their guidelines again and now recommend to start ART in all children less than five years regardless of their CD4 count (8) . Therefore, only HIV-infected children of five years or older now require a CD4 count as part of the management algorithm.
However there are still settings where CD4 testing is still not available, or cost are too high, in which case the WHO clinical classification system i.e. 'clinical staging', occasionally combined with a total lymphocyte count (TLC), is used (7) .
Clinical staging may have major limitations because most clinical conditions used in the classification system are difficult, if not impossible, to diagnose especially in the same resource-limited settings where CD4 testing is not readily available (9) . Further, the correlation of clinical staging with CD4 counts is poor, resulting in the misclassification of severely immune compromised children with low CD4 counts as clinical stage 1 or 2 (7) . As a consequence, in resource-limited settings a considerable number of HIV-infected children that require ART are not enrolled in the government programmes and do not receive potentially life-saving ART.
These risks may be reduced by the introduction of alternative markers to identify adequate CD4. A well-known alternative marker used by the WHO is the TLC (7) . Studies in resource-limited settings have found only a moderate correlation and a low sensitivity of TLC as a surrogate marker for CD4 (4, (10) (11) (12) . Other markers that have been suggested in combination as surrogates for CD4 count include haemoglobin, platelet count, serum albumin and growth parameters (1, (13) (14) (15) (16) (17) . It remains unclear which marker or combination of markers best predicts CD4 values in African children because they have not previously been evaluated together in one 32 Chapter 2 study population in a single study. We have therefore evaluated TLC, haemoglobin (Hb), platelet count, serum albumin and growth parameters as correlates of CD4 values.
Methods

Methods| Study population
A cross-sectional study of HIV-infected children was conducted in the Paediatric ART clinic of Queen Elizabeth Central Hospital, Blantyre, Malawi, from 2008-2010.
On initial presentation to the clinic, all children underwent a full clinical evaluation including clinical staging. ART was commenced in those that were eligible according to the recommendations of the Malawi national guidelines. For purposes of this study, following written informed consent we enrolled HIV-infected children aged between 18 months and 18 years that were not yet eligible to start ART based on clinical staging according to the Malawi national guidelines which had been adapted from the WHO 2006 guidelines (7) . This included children with stage 1, 2 or stage 3a disease (pulmonary tuberculosis, HIV-related chronic lung disease or weight for age < 2SD). Children who had received a blood transfusion in the previous month or children with a known cause of anaemia (e.g. sickle cell disease) were excluded.
Methods| Laboratory
HIV antibody testing (Abbott Determine HIV-1/2 Test, Uni-Gold HIV test) and counselling had been conducted prior to attending the HIV clinic. At enrolment for this study, blood was taken for full blood count (Beckman Coulter HMX, Beckman coulter, CA USA), CD4 count (flow cytometry, Becton Dickinson, CA USA), C-reactive protein and albumin (Modular P800 and Modular Analytics E170 systems, on a Roche 9000). Table 1 lists the WHO definitions applied in this study for anaemia, malnutrition and age-related indicators to start ART (4, 6, 7, (18) (19) (20) . Young children are less than five years of age; older children are aged 5-18 years.
Methods| Definitions
Methods| Statistical analysis
Data were entered and analysed using SPSS version 19.0 for MAC (IBM ® ). Baseline variables were analysed with Chi-square for dichotomous and categorical frequencies and with non-paired T-test or ANOVA for continuous variables. Univariate analysis and multi-variant linear regression analysis were used for the analysis of associations between CD4 count and CD4 percentage with potential predictors (haemoglobin, TLC, platelet count, albumin and growth parameters). CD4 cut-offs are based on the WHO 2013 guidelines (8) . Predictors were included in a backward multi-variant model if a trend towards a univariate association was observed (p<0.1). The analysis was performed separately for children of less than 5 years and those aged 5 years and older (17) . To optimize sensitivity and specificity, data were visualised by linear curves whereby potential new cut-offs were defined. All p-values presented are two-tailed and a significance level of <0.05 was used.
Methods| Ethical approval
The study was approved by the Research Ethics Committee of the College of Medicine, University of Malawi. The purpose of the study was explained to the guardians of each patient in Chichewa and written informed consent was obtained before inclusion into the study.
Results
In total, 417 children were enrolled in the study of which 261 (61%) were aged 5 years or older. Stage 1, 2 and 3a disease were diagnosed in 50%, 24% and 26% of children, respectively ( Table 2) . As defined by the selection criteria, none of the children qualified to start ART based on clinical staging at the time of enrolment. Optimal cut-offs were in general higher than WHO cut-offs: 3000 versus 2000 cells/ mm 3 for the 59-96 months age group and 2500 versus 1200 cells/mm 3 for children 2 36 Chapter 2 
Discussion
This is the first study to simultaneously evaluate all previously identified markers that are potential alternatives to CD4 values in children not eligible to start ART based on clinical staging alone. There are a number of important findings. First, if the WHO 2013 guidelines are applied, the majority (59%) of older children that did not qualify for ART on the basis of clinical staging alone were in fact eligible for ART on the basis of CD4 results. Second, a low TLC was associated with a low CD4-count in older children but sensitivity could be markedly improved by adopting cut-offs that are different to those currently recommended by WHO guidelines. Thirdly, we did not identify a reliable alternative predictor of CD4 percentage for the young children, which is consistent with previous studies that have recognised that clinical staging is a poor indicator of CD4 percentage in young children (11, 22, 23) .
Since the study was designed several important changes took place: ART is given to all young children irrespective of CD4 values and CD4 testing has become more easily available (8) . Still CD4 testing remains costly and (reliable) results are not always available in sub-Saharan African clinics. Therefor alternative markers for CD4 counts are still relevant in children aged 5 years or older. Using the 2013 criteria, 59% of the older children eligible for ART in our study would not have been identified using clinical criteria alone. We aimed to optimise the cut-off values if using TLC to improve sensitivity. Our findings are consistent with those from a previous study of Kenyan children that suggested that TLC cut-off values should be increased (24) . That study evaluated the cut-off against WHO 2006 guidelines and suggested that 3000 cells/mm 3 would be an optimal cut-off for older children. Our findings suggest that the optimal TLC cut-off for older children would be 2500 cells/ mm 3 .
The original WHO recommendations for using TLC published in 2006 were based on the correlation between TLC and a decline in CD4 count over time in children in USA and Europe (25, 26) . Several studies have shown that TLC is a good predictor of mortality but correlates poorly with CD4 count (12, 23, 27, 28) . Furthermore, TLC varies between different populations as well as between individual (25, 26) . Findings in African children may differ from counterparts in the USA and Europe for a number of reasons. Variations between environmental, nutritional and genetic factors are likely to have an impact (29, 30) . Secondly, the recommended cut-offs were derived from cohort studies of HIV infected children irrespective of their clinical staging. They were not designed to detect children with low CD4 results that had no clinical signs of advanced HIV disease and yet this is the population for which TLC is currently being used. Although raising the cut-off will lower the threshold to put children on ART, we think there is a need to reconsider the TLC cut-offs values as per WHO guidelines to commence ART (7) .
Low serum albumin was associated with clinical staging and CD4 values in the univariate analysis, but not in the multi-variant model. This association has not previously been studied in paediatric HIV populations. Our findings are consistent with studies in HIV-infected adults that reported that an association of serum albumin with HIV disease progression (14, 31) . Low albumin levels can be an acute phase response (16, 32, 33) , or caused by malnutrition or chronic disease (31, 34, 35) . The fact that low albumin was not retained in a multi-variant model including markers for malnutrition suggests that this marker has limited added value over anthropometry alone.
Anaemia is a predictor of disease progression among HIV-infected children and adults (25, 36, 37) . Although we found a difference in haemoglobin between the WHO staging groups, we were unable to find an association between low haemoglobin and CD4 values. Our results are consistent with the few studies conducted in African HIV-infected children showing that although anaemia may be a useful criterion to assess disease severity, defining cut-offs to guide the start of ART appears impossible (25, 37) . Like anaemia, thrombocytopenia has been associated with disease progression and death in HIV-infected children in western countries (27, 28, 32, 38, 39) . However, we did not find associations between platelet count and CD4 sub-groups or clinical stage. In our setting thrombocytes may have been influenced by co-infections such as malaria (29) .
Conclusion
In summary, the majority of children that would not be eligible for ART on clinical staging had CD4 count eligible for ART according to current WHO guidelines. For older HIV-infected children in the African setting, the TLC cut-off when used as an alternative marker to CD4 count, when CD4 is not readily available, for decisions about commencing ART may need to be increased. 
